NCT01409161View on ClinicalTrials.gov

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 5, 2011

Primary Completion Date

December 18, 2025

Study Completion Date

December 18, 2025

Conditions
Acute Promyelocytic Leukemia With PML-RARA
Interventions
DRUG

Arsenic Trioxide

Given IV

DRUG

Gemtuzumab Ozogamicin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Tretinoin

Given PO

Trial Locations (5)

77030

RECRUITING

M D Anderson Cancer Center, Houston

77058

RECRUITING

MD Anderson Regional Care Center-Bay Area, Nassau Bay

77094

RECRUITING

MD Anderson Regional Care Center-Katy, Houston

77384

RECRUITING

MD Anderson Regional Care Center-The Woodlands, The Woodlands

77478

RECRUITING

MD Anderson Regional Care Center-Sugar Land, Sugar Land

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER